Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer

European Urology Open Science - Tập 50 - Trang 27-30 - 2023
Chaoran Ma1, Caroline Ericsson2, Sigrid V. Carlsson3,4,5, Hans Lilja6,7, Adam Kibel8, Rebecca E. Graff2,9, Anna Plym2,8,10, Edward Giovannucci2, Lorelei A. Mucci11, Mark A. Preston8, Kathryn L. Penney1,2
1Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
3Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
4Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
5Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
6Department of Pathology and Laboratory Medicine and Medicine, GU-Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
7Department of Translational Medicine, Lund University, Malmö, Sweden
8Division of Urology, Brigham and Women’s Hospital, Boston, MA, USA
9Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA, USA
10Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
11Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA

Tài liệu tham khảo

Frånlund, 2022, Results from 22 years of follow-up in the Göteborg randomized population-based prostate cancer screening trial, J Urol, 208, 292, 10.1097/JU.0000000000002696 Martin, 2018, Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial, JAMA, 319, 883, 10.1001/jama.2018.0154 Preston, 2016, Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer, J Clin Oncol, 34, 2705, 10.1200/JCO.2016.66.7527 Preston, 2019, Baseline prostate-specific antigen level in midlife and aggressive prostate cancer in Black men, Eur Urol, 75, 399, 10.1016/j.eururo.2018.08.032 Carlsson, 2014, Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study, BMJ, 348, g2296, 10.1136/bmj.g2296 Kovac, 2020, JAMA Netw Open, 3, e1919284, 10.1001/jamanetworkopen.2019.19284 Conti, 2021, Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction, Nat Genet, 53, 65, 10.1038/s41588-020-00748-0 Gann, 2002, Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation, J Urol, 167, 2427, 10.1016/S0022-5347(05)64998-1 Ma, 2021, Circulating insulin-like growth factor 1-related biomarkers and risk of lethal prostate cancer, JNCI Cancer Spectr, 6, pkab091, 10.1093/jncics/pkab091 Klein, 2022, Prostate cancer polygenic risk score and prediction of lethal prostate cancer, NPJ Precis Oncol, 6, 25, 10.1038/s41698-022-00266-8
Thông tin
Thông tin xuất bản

European Urology Open Science

Tập 50

27-30

Thông tin tác giả